 |
Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P) |
|---|---|
| Trade Name | |
| Orphan Indication | Myelofibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2011-06-01 00:00:00 |
| Sponsor | Gilead Sciences, Inc.;199 E. Blaine St.;Seattle, Washington, 98102 |
Related Access Program